Loading patent…
AssigneeQilu Puget Sound Biotherapeutics Corporation
InventorsZhi Liu, Victor Hermand, Hua Liu, Wei Yan
Estimating the term…
Provide herein are variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies optionally produced by a host cell line, nucleic acids encoding the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies, host cells containing such nucleic acids, and methods of treatment using the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies, or nucleic acids encoding the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies described herein. Also described are methods of producing the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies in host cells.
A variant-Fc-region comprising a set of amino acid substitutions compared to native human IgG1, IgG2, or IgG4, selected from:
A substantially pure heterodimeric-variant-Fc-region antibody composition, comprising a set of amino acid substitutions compared to native human IgG1, IgG2, or IgG4, wherein said composition comprises:
A humanized anti-hCLDN18.2 monoclonal antibody, wherein said antibody comprises a variable heavy chain (VH) amino acid sequence corresponding to SEQ ID NO:52;
Dependencies are inferred from the claim text.